Journal Article

A pharmacokinetic study of lipegfilgrastim in children with Ewing family of tumors or rhabdomyosarcoma

Lamson, Michael J., Bias, Peter, Belogurova, Margarita B., Csóka, Mónika, Lammerich, Andreas, Kizyma, Zoryana P., Garami, Miklós, Buchner, Anton

2017

Overview

Purpose Neutropenia is a common complication from chemotherapy, limiting optimal dosing and treatment. Lipegfilgrastim is a long-acting granulocyte colony-stimulating factor developed for the management of chemotherapy-induced neutropenia. The objectives of this phase 1, multinational, open-label, single-arm study were to characterize the pharmacokinetics (PK) and pharmacodynamics (PD) of a single body weight-adjusted dose of lipegfilgrastim and to evaluate the efficacy, safety, and tolerability of the drug in children with Ewing family of tumors or rhabdomyosarcoma treated with myelosuppressive chemotherapy. Methods Enrolled patients received lipegfilgrastim (100 µg/kg) 24 h after the last chemotherapy treatment in week 1. Patients were stratified into three age groups: 2 to <6, 6 to <12, and 12 to <18 years. Blood samples for PK analyses were obtained at baseline and at 3, 8, 24, 30, 48, 72, 96, 144, and 240 h postdose for the two oldest groups and up to 144 h in the youngest group. Results Twenty-one patients were enrolled and received lipegfilgrastim, seven in each age group. Lipegfilgrastim exposure levels were comparable across age groups, with concentrations maintained over a prolonged period after a single injection. Differences in PD were mainly associated with chemotherapy type. Most investigator-reported adverse events were attributed to chemotherapy and not to lipegfilgrastim. Severe adverse events were noted in 57% of patients; febrile neutropenia, leukopenia, neutropenia, and thrombocytopenia were more frequent among the oldest patients. Conclusions Results support the use of a body weight-adjusted dose to achieve equivalent initial peak exposure levels of lipegfilgrastim in children of various ages.

• Publisher: Springer Berlin Heidelberg,Springer Nature B.V
• Subject: Adolescent / blood / Bone Neoplasms - drug therapy / Cancer Research / Child / Child, Preschool / drug therapy / drugs / family / Female / Filgrastim / granulocyte colony-stimulating factor / Granulocyte Colony-Stimulating Factor - administration & dosage / Granulocyte Colony-Stimulating Factor - adverse effects / Granulocyte Colony-Stimulating Factor - pharmacokinetics / Humans / Male / Medicine / Medicine & Public Health / neutropenia / Oncology / Original / Original Article / pharmacodynamics / pharmacokinetics / Pharmacology/Toxicology / Polyethylene Glycols / Recombinant Proteins - administration & dosage / Recombinant Proteins - adverse effects / Recombinant Proteins - pharmacokinetics / Rhabdomyosarcoma - drug therapy / Sarcoma, Ewing - drug therapy / thrombocytopenia